|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2000-7-14
|
|
pubmed:abstractText |
Considerable morbidity and mortality are consequences of the myeloablative chemoradiotherapy utilised in conventional allogeneic marrow transplantation. This has generally restricted such potentially curative treatment to patients <50-55 years with normal organ function. Recent studies suggest that purine-analogue based non-myeloablative regimens are sufficiently immunosuppressive to facilitate allogeneic donor cell engraftment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0004-8291
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
308-14
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10868492-Adult,
pubmed-meshheading:10868492-Bone Marrow Transplantation,
pubmed-meshheading:10868492-Female,
pubmed-meshheading:10868492-Graft vs Host Disease,
pubmed-meshheading:10868492-Hematologic Neoplasms,
pubmed-meshheading:10868492-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:10868492-Humans,
pubmed-meshheading:10868492-Immunosuppressive Agents,
pubmed-meshheading:10868492-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:10868492-Male,
pubmed-meshheading:10868492-Middle Aged,
pubmed-meshheading:10868492-Vidarabine
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Mini-allografts' for haematological malignancies: an alternative to conventional myeloablative marrow transplantation.
|
|
pubmed:affiliation |
Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Vic.
|
|
pubmed:publicationType |
Journal Article
|
